


SERIAL NO. 09/762,538 ATTORNEY DOCKET NO.: 14014.0349U1 DOCKET Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-NO. 80) APPLICANT: Egan, et at. PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT GROUP: Unassigned FILING DATE: February 8, 2001 (Use several sheets if necessary) U.S. PATENT DOCUMENTS FILING DATE SUBCLASS CLASS NAME DATE DOCUMENT NO. EXAMINER IF APPROPRIATE INITIAL FOREIGN PATENT DOCUMENTS 11/23/95 PCT WO 95/31214 Α1 09/02/99 PCT WO 99/43705 A2 OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Mashima et al. "Formation of Insulin-Production Cells from pancreatic Acinar AR42J Cells by **A3** Hepatocyte Growth Factor." Endocrinology 137: 3969-3976, 1996. Gefel et al. "Glucagon-Like Peptide I Analogs: Effects on Insulin Secretin and Adenosine A4 3',5'-Monophosphate Formation. \* Endocrinology 126:2164-68, 1990. De Ore et al. "The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test." J. Geront. 52: B245-249, 1997 A5 Drucker et al. "Glucagon-like Peptide 1 stimulates insulin gene expression and increases cyclic AMP in a rat islet cell line." Proc. Natl. Acad. Sci. USA. 84: 3434-3438, 1987. A6 Egan et al. "Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-11 adipocytes: one of several potential extrapancreatic sites of GLP-1 Α7 action. \* Endocrinology 135: 2070-2075, 1994. Elahi, et al. "The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (737) in normal and diabectic subjects." Regulatory A8 Peptides 51: 63-74, 1994. Elahi, et al. "The effect of age and glucose concentration on insulin secretion by the Α9 isolated perfused pancreas." Endocrinology 116; 11-16, 1985. Federal Register 63, Friday, February 20, 1998, p. 8652. A10 Fehmann and Habener et al. "Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proisulin biosysthesis in insulinoma BTC-1 cells." A11 Endocrinology 130: 159-166, 1992. Fehmann et al. "Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-dependent Insulin Releasing polypeptide. " Endocrine Rev. 16:390-410, 1995. A12



		The market an antagonist
$\mathcal{D}$	A13	Goke et al. "Exendin-4 is a potent agonist and truncated exdenin-(9-39)-allite an antagonist at the GLP-1-(7-36)-amide receptor of insulin-secreting β-cells." J.Biol. Chem. 268: 19650-19655, 1993.
1	A14	Gromada et al. "Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic $\beta$ -Cells by both Proximal and Distal Regulatory Steps in Stimullus-secretion Coupling." Diabetes 47:57-65, 1998.
	A15	Gutniak et al. "Antidiabetogentic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus." N. Engl. J. Med. 326: 1316-1322, 1992.
	A16	Guz et al. "Expression of murine STF-1, aputative insullin gene transcription factor, in $\beta$ cells of pancreas, duodenal epithelium and pancreatic excrine and endocrine progenitors during ontogengy." Development 121: 11-18, 1995.
	A17	Hawes et al. "Distinct pathways of $G_i$ -and $G_q$ -mediated mitogen-activated protein kinase activaton" J. Biol. Chem. 270: 17148-17153, 1995.
_	A18	Holz et al. "Activation of a cAMP-regulated Ca2+-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like-peptide-1." J. Boil. Chem. 270: 17749-17757, 1995.
	A19	Hosokawa et al. "Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37)." J. Clin. Invest. 97: 180-1860, 1996.
	A20	Kimura et al. "High concentrations of cholecystokinin octapeptide suppress protein kinase cactivity in guinea pig pancreatic acini." Peptides 17: 917-925, 1996.
	A21	Malhotra et al. "Exendin-4, a new peptide from heloderma suspectum vemon, potentiates cholecystokinin-induced amylase from rat pancreatic acini." Regul. Pept. 41: 149-156, 1992.
	A22	Mashima et al. "Betacellulin and activin A. coordinately convert amylase-secreting AR42J cells into insullin-secreting cells." <i>J. Clin. Invest.</i> 97:1647-1654, 1996.
	A23	Montrose-Rafizadeh et al. "High potency antagonists of the pancreatic glucagon-like peptide-1 receptor." J. Biol. Chem. 272:21201-21206, 1997.
	A24	Montrose-Rafizadeh et al. "Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanism of action." Endocrinology 135: 589-594, 1994.
	A25	Montrose-Rafizdeh et al. "Novel signal transduction and peptide specificity of gluccagon-like peptide receptor in 3T3-L1 adipocytes." J. Cell. Physiol. 172: 275-280, 1997.
	A26	Nathan et al. "Insulinotropic action of glucagonlike-peptide-1-(7-37) in diabetic and nondiabetic subjects." Diabetics Care 15:270-276, 1992.
	A27	Nuack et al. "preserve incretin activity of Gucagon-like peptide 1 (&-36) amide but not of synthetic human gastirc inhibitory polypeptide in patients with Type-2 diabetes mellitus." J. Clin. Invest. 91:301-307, 1993.
	A28	Nauck et al. "normalization of fasting hyperglycemia by exogenuos glluagoon-like peptide 1 (7-36) amide in Type 2 (non-insulin-dependent)0 diabetic patients." Diabetologia 36:741-744, 1993.
	A29	Orskov et al. " Glucagon-like peptide-1, a new hormone of the entero-insular axis."
	A30	Perfetti et al. "Age-dependent reduction on insulin secretion and insullin mRNA in isolated islets from rats." Am. J. Physiol. 269: E983-990, 1995.
	A31	Ritzel et al. "Pharacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships."  Diabetologia 38: 720-725, 1995.
	A32	Diabetes Metabolism Rev. 12:
	A33	in alaring of the pancreatic beta cell receptor for the gluco-



D	A34	Thorens et al. "Cloning and functional expression of the GLP-1 receptor: Dempstration that exendin-4 is an agonist and exendin-3(9-39) is an antagonist of the receptor." Diabetes 42: 1678-1682, 1993.		
1	A35	Thorens and Waeber et al. " Glucagon-like peptide-1 and the control of insulin secretion in the normal state and in NIDDM." Diabetes 42: 1219-1225, 1993.		
	A36	Valverde and Villanueva-Penacarrillo et al. "In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat." Acta Physiologica Scandinavica 157:359-360, 1996.		
	A37	Wang et al. "Glucagon-like peptides-1 can reverse the age related decline in glucose tolerance in rats. J. Clin. Invest. 99: 2883-2889, 1997.		
	A39	Wang et al. "Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stablity of components of the insulin secretory system in RIN 1046-38 cells."  Endocrinology 136: 4910-4917, 1995.		
	A40	Wang et al. "GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells." <i>Moll. Cell. Endo</i> 116: 81-87, 1996.		
	A41	Wang et al. "Glucagon-like peptide-1 is a phsyiological incretin in rat." J. Clin. Invest. 95: 417-421, 1995.		
	A42	Widmann et al. "Desensitization and phosporylation of the glucagon-llike peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-Myristate 13-acetate." Mol. Endocrinol. 10: 62-75, 1996.		
	A43	Willms et al. "Gastric emptying, glucose response, and insulin secretion after a liquid test meal: effects of exgenous glucagon-like peptide-1-(7-36) amide in Type 2 (non-insulin-dependent) diabetic patients." J. Clin. Endocrinol. Metab. 81: 327-332, 1996.		
V	A44	Yada et al. "Glucagon-like peptide-1-(7-36) amide and a rise in cyclic adenosine 3', 5'-monophosphate increase cyosolic free $Ca^{2^+}$ in rat pancreatic $\beta$ -cells by enhancing $Ca^{2^+}$ channel activity." Endocrinology 133: 1685-1692.		
EXAMINER: DONA ARMA DATE CONSIDERED: 1/16/03				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication				

W104059.WPD